Rentosertib
Rentosertib (also known as ISM001‑055 and INS018_055) is an investigational new drug that under evaluation for the treatment of idiopathic pulmonary fibrosis (IPF).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Rentosertib (also known as ISM001‑055 and INS018_055) is an investigational new drug that under evaluation for the treatment of idiopathic pulmonary fibrosis (IPF). It targets TNIK (TRAF2 and NCK-interacting protein kinase). It is asserted to be the first drug generated entirely by generative artificial intelligence to reach phase 3 human clinical trials, and the first to target a novel, AI-discovered biological pathway.
Development
Rentosertib was developed by Insilico Medicine using a generative AI platform designed to identify novel disease-associated targets and rapidly design optimized small-molecule inhibitors. TNIK was identified as a central regulator of fibrosis and inflammation in IPF. Rentosertib selectively inhibits TNIK, and progressed from target discovery through phase 0 and 1 clinical trials in under 30 months.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375515422 under CC BY-SA 4.0; modifications have been made.